A Phase 2 12-Week Adaptive Open Label Sequential Cohort Trial to Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of PF06730512 Following Multiple Doses in Adult Subjects with Focal Segmental Glomerulosclerosis (FSGS)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
